tbuckley/cabot-search huggingface dataset:
Association Between Gadolinium Contrast Exposure and the Risk of Parkinsonism
Authors: Blayne Welk, Eric McArthur, Sarah A. Morrow, Penny MacDonald, Jade Hayward, Andrew Leung, Andrea Lum
Journal: JAMA (2016)

Between Gadolinium Contrast Exposure and the Risk of ParkinsonismGadolinium-based contrast agents are used for enhancement during magnetic resonance imaging (MRI).Safety concerns have emerged over retained gadolinium in the globus pallidi. 1,2Neurotoxic effects have been seen in animals and when gadolinium is given intrathecally in humans. 1 In July 2015, the US Food and Drug Administration stated that it was unknown whether gadolinium deposits were harmful.The substantia nigra (affected in Parkinson disease) directs voluntary movement via signals to the globus pallidi.Consequences of damage to the globus pallidi may include parkinsonian symptoms. 3 We conducted a population-based study to assess the association between gadolinium exposure and parkinsonism. 96
Soluble hemoglobin scavenger receptor CD163 (sCD163) predicts mortality of community-acquired pneumonia
Authors: Yuzo Suzuki, Yasunori Enomoto, Koushi Yokomura, Hironao Hozumi, Masato Kono, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Takafumi Suda
Journal: Journal of Infection (2016)
Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00).
Authors: Jan Lehmann, Michael Kuehn, Claus Fischer, Bjoern Volkmer, Friedrich von Rundstedt, Peter Albers, Eduard Becht, Andreas Bannowsky, Rainer Hofmann, Sigrun Langbein, Margitta Retz, Michael Stoeckle
Journal: Journal of Clinical Oncology (2013)

250 Background: Cisplatin-based chemotherapy (CBC) has been widely used in trials of adjuvant therapy for LABC after RC. A high proportion of patients are unfit for CBC after RC for LABC. We therefore performed a prospective randomized phase III trial on G-monotherapy administered as adjuvant therapy (G-adj) vs in case of progression (G-prog) in pts not suitable for CBC. Methods: Between 7/2000 and 12/2008 120 of 178 planned pts with LABC unfit for CBC were randomized between 6 adjuvant cycles of G (q3w) starting within 12 wks after RC and G in case of disease progression. The primary endpoint of the trial was progression-free survival (PFS). Secondary endpoints included cancer-specific (CSS) and overall survival (OS) as well as treatment related toxicity. Results: The trial of 178 planned pts was closed early due to slow accrual. Of 120 randomized pts from 29 centers 114 were eligible for analysis. Median age of 81 male and 33 female pts was 72 (45-82) years. Lymph-node positive disease was found in 52/114 (47%) of pts at the time of surgery. The intention-to-treat analysis demonstrated a 10% difference in PFS after 3 years 50% (G-adj) vs 40% (G-prog) with a median PFS of 23 mo (G-adj) vs 17 mo (G-prog). The difference in PFS was not statistically significant (nss) (p= 0.335; HR 1.375, 95%CI 0.719 - 2.627). CSS at 3ys: 56% (G-adj) vs 50% (G-prog) with a median CSS of 49 mo (G-adj) vs 38 mo (G-prog). The difference in CSS was nss (p= 0.622; HR 1.166, 95%CI 0.632 - 2.149). OS at 3ys: 49% (G-adj) vs 48% (G-prog) with a median OS of 32 mo (G-adj) vs 31 mo (G-prog). The difference in OS was nss (p= 0.426; HR 1.225, 95%CI 0.743 - 2.018). Treatment with G was usually well tolerated, with less than 15% grade 3/4 toxicities..There was one treatment related death in the G-adj arm. Conclusions: The study-hypothesis of a 15% difference in PFS after 3 years in favor of G-adj vs G-prog could not be confirmed. Nevertheless a marked difference in survival in favor of G-adj was shown by Kaplan-Meier plots regarding PFS, CSS and OS within the first 24 months after RC. Clinical trial information: NCT00146276.
Note on the Enzymatic Activity of Normal and Neoplastic Tissues of the Rat
Authors: Jesse P. Greenstein, Florence M. Leuthardt
Journal: JNCI Journal of the National Cancer Institute (1946)

Note on the Enzymatic Activity of Normal and Neoplastic Tissues of the Rat Get access Jesse P. Greenstein, Jesse P. Greenstein principal biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Florence M. Leuthardt Florence M. Leuthardt junior biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 6, Issue 6, June 1946, Page 317, https://doi.org/10.1093/jnci/6.6.317 Published: 01 June 1946
Bioassay on Polyvinylpyrrolidones With Limited Molecular Weight Range
Authors: W. C. Hueper
Journal: JNCI Journal of the National Cancer Institute (1961)

Two specially prepared polyvinylpyrrolidones (PVP's), one with a molecular weight range between about 2,000 and 38,000 and the other with a molecular weight range from approximately 4,000 to 80,000, were injected repeatedly as 25 percent solutions in physiologic saline into the abdominal cavities of rats and rabbits. The macromolecular material of both PVP's was retained in the organs of rats despite the relatively low maximal molecular weight of one of the PVP's. However, this PVP passed the glomerular filter of the rabbits and thus was not stored. The glomerular filter of rats and rabbits differed in pore size. The degree of storage of the PVP's tested did not exert any stimulating effect upon the production of cancers. In fact, there was evidence that one of two PVP's used for comparative purposes and having an average molecular weight of 50,000 might have interfered with the development of spontaneous cancers. Whenever carcinogenic properties of PVP's were present, they did not seem to be related to any physical properties of the macromolecules.
Gene Expression Profiling Reveals Fundamental Differences between Leukemic Stem Cells (Lin-CD34+CD38−) and Mature Blasts (Lin−CD34+CD38+) of Acute Myeloid Leukaemia (AML) Patients.
Authors: Kazem Zibara, Daniel Pearce, David Taussig, Spyros Skoulakis, Simon Tomlinson, Emilie Bureau, Bryan D. Young, Dominique Bonnet
Journal: Blood (2005)
A medical locum service as a site for sentinel influenza surveillance
Authors: J Turner, H Kelly
Journal: Eurosurveillance (2005)

Surveillance of influenza in the countries of the European Union includes a sentinel network of general practitioners reporting cases of influenza-like illness (ILI), the collection of specimens for virological testing, and laboratory reporting of influenza diagnoses. In Victoria, Australia we have a similar sentinel surveillance system, with ILI defined by fever, cough and fatigue, and influenza seasons described by thresholds. The coordination of sentinel general practices can, however, be time consuming and expensive. For the last two influenza seasons we have used a deputising medical locum service as a sentinel site for influenza surveillance. We are not aware of such a service being used as a sentinel site elsewhere in the world. In both retrospective and prospective comparisons, we have shown that ILI surveillance patterns from sentinel general practices are very similar to those from the locum service. Because of its timeliness, flexibility, patient mix and geographic spread, locum service surveillance is able to supplement sentinel ILI surveillance and may also have a role in the recognition of emerging disease patterns. This is likely to be true not only in Australia but also in countries of the European Union.
Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth
Authors: DeannaLee M. Beauvais, Oisun Jung, Yang Yang, Ralph D. Sanderson, Alan C. Rapraeger
Journal: Cancer Research (2016)

Abstract Syndecan-1 (Sdc1/CD138) expression is linked to disease severity in multiple myeloma, although the causal basis for this link remains unclear. Here we report that capture of the IGF1 receptor (IGF1R) by Sdc1 suppresses ASK1-dependent apoptosis in multiple myeloma cells. Sdc1 binds two different fractions of IGF1R, one that is constitutively active and a second that is activated by IGF1 ligand. Notably, IGF1R kinase activity in both fractions is blocked by synstatinIGF1R (SSTNIGF1R), a peptide that inhibits IGF1R capture by Sdc1, as well as by a truncated peptide (SSTNIGF1R-T) that appears to be specific for multiple myeloma cells. Mechanistically, we show that ASK1 is bound to active IGF1R and inhibited by Tyr and Ser83/Ser966 phosphorylation. When IGF1R engagement with Sdc1 is blocked by SSTNIGF1R, ASK1 becomes activated, and initiates JNK- and caspase-3–mediated apoptosis. In pharmacologic tests, we find SSTNIGF1R is highly stable in human plasma and displays a half-life of 27 hours in mice, wherein it significantly reduces both the size and neovascularization of CAG myeloma tumor xenografts. Taken together, our results offer a preclinical proof of concept and mechanistic rationale for the exploration of SSTNIGF1R as an experimental therapeutic to dually attack multiple myeloma tumor cell survival and tumor angiogenesis. Cancer Res; 76(17); 4981–93. ©2016 AACR.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
Authors: Alexandra Albertsson-Lindblad, Arne Kolstad, Anna Laurell, Riikka Räty, Kirsten Grønbæk, Jan Sundberg, Lone Bredo Pedersen, Elisabeth Ralfkiær, Marja-Liisa Karjalainen-Lindsberg, Christer Sundström, Mats Ehinger, Christian Geisler, Mats Jerkeman
Journal: Blood (2016)
Adenosine Selectively Depletes Alloreactive T Cells to Prevent GVHD While Conserving Immunity to Viruses and Leukemia
Authors: Greg D Whitehill, Shoba Amarnath, Pawel Muranski, Keyvan Keyvanfar, Minoo Battiwalla, Austin J. Barrett, Dhanalakshmi Chinnassamy
Journal: Molecular Therapy (2016)

Selective depletion (SD) of alloreactive T cells from allogeneic hematopoeitic stem cell transplants to prevent graft-versus-host disease (GVHD) without compromising immune reconstitution and antitumor responses remains a challenge. Here, we demonstrate a novel SD strategy whereby alloreacting T cells are efficiently deleted ex vivo with adenosine. SD was achieved in human leukocyte antigen (HLA) mismatched cocultures by multiple exposures to 2 mmol/l adenosine over 7 days. Adenosine depleted greater than to 90% of alloproliferating T cells in mismatched, haploidentical, and matched sibling pairs while conserving response to third-party antigens. Alloreactive CD4 and CD8 T cells were targeted for depletion while NK and B cells were preserved. Our novel approach also preserved nonalloreactive naive, central, and effector memory T-cell subsets, Tregs, and notably preserved T-cell responses against DNA viruses that contribute to transplant related mortality after allogeneic hematopoeitic stem cell transplants. Additionally, T cells recognizing leukemia-associated antigens were efficiently generated in vitro from the cell product post-SD. This study is the first to demonstrate that adenosine depletion of alloactivated T cells maintains a complete immune cell profile and recall viral responses. Expansion of tumor antigen-specific subsets postdepletion opens the possibility of generating T-cell products capable of graft-versus-tumor responses without causing GVHD.
Patients' and observers' assessments of process and outcome in group therapy: a follow-up study
Authors: R J Cabral, J Best, A Paton
Journal: American Journal of Psychiatry (1975)

A six-month follow-up investigation of process and outcome in group therapy was conducted by the authors and patients in two therapy groups. The results indicated that although there were discrete stages in the therapeutic sequence, acceptance was the most beneficial process variable for both groups.
A Perspective on Hospice Reform and Additional Caregiver Support
Authors: Jessica Conway Church, Shane Eleanor Conway McCoin
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A Study Of Myc and Mcl-1 Transcript Levels Before and During Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia Patients
Authors: Vasiliki Papadopoulou, Nefeli-Christina Kontandreopoulou, Maria Roumelioti, Maria Sofotasiou, Panagiotis Theodorou Diamantopoulos, Aikaterini Polonyfi, Amalia Anastasopoulou, Eleni Variami, Panayiotis Panayiotidis, Nora-Athina Viniou
Journal: Blood (2013)
Abstract 3677: Effects of Aging and Endogenous Extracellular Superoxide Dismutase on Endothelial Function in Mice
Authors: Donald D Lund, Yi Chu, Jordan D Miller, Donald D Heistad
Journal: Circulation (2008)

A gene variant of extracellular superoxide dismutase (ECSOD) that impairs normal vascular localization is associated with increased risk of ischemic heart disease in people over 70 years old. ECSOD may be reduced with aging and a variety of disease states, and we have reported previously that gene transfer of ECSOD improves endothelial vasomotor function in both old and diseased animals. The role of endogenous/residual levels of ECSOD, however, in modulation of vasomotor function during aging is not clear. Thus, the purpose of this study was to determine whether genetic deletion of endogenous ECSOD predisposes to endothelial dysfunction in old mice. Gene expression (qRT-PCR) and vasomotor function (aortic rings) were measured in adult (10 –12 mo old) and old (28 –31 mo old) wild type (ECSOD +/+ ) and ECSOD knockout (ECSOD −/− ) mice. Compared to young ECSOD +/+  mice, expression of ECSOD, but not CuZnSOD or MnSOD, was reduced in old ECSOD +/+  animals by 40±8% (mean±SE, p  −/−  mice. In WT mice there was mild impairment in maximum relaxation to acetylcholine during aging (young ECSOD +/+  = 89±2%, old ECSOD +/+  = 75±4%, p  −4 ) in young adult ECSOD-deficient mice (75 ± 3%) compared to young adult wild type mice (p  −/−  mice (47 ± 5%, p  +/+  or ECSOD −/− mice, or in old ECSOD +/+  mice. Tempol, however, improved endothelial function in old ECSOD −/−  mice (47 3 ± vs 71 ± 5%, p
Diffuse and/or superficial p53 expression in Barrett mucosa correlates with severe dysplasia
Authors: A. Driessen, K. Geboes, T. Lerut, E. van Cutsem, K. Haustermans, N. Ectors
Journal: Journal of Clinical Oncology (2005)

4178 Background: Barrett esophagus is the precursor of most esophageal adenocarcinomas. Dysplasia or intraepithelial neoplasia (IEN) is the first step in the sequence which can be recognized with routine morphology in endoscopic biopsies. This diagnosis is however difficult in biopsies with high interobserver variability for low-grade IEN. To solve this diagnostic challenge, immunohistochemistry for p53, a tumor-supressor marker, has been proposed. The features which are useful for assessment of p53-immunoreactivity (p53+) and their clinical and pathogenetic implications are still unclear. Aim: To evaluate the relationship between p53+ and morphological changes and Ki-67-positivity (Ki-67+), a proliferation marker, in Barrett mucosa. Methods: Histology and immunohistochemistry (p53, clone DO-7;Ki-67, clone Mib-1) was performed on 20 operation specimens (short segment Barrett n=10, long n=10) (M/F 3, 66±10 yr) (IEN: low grade n=3, high grade n=3, adenocarcinoma: in situ n=2, T1 n=12; 100% of lesions p53+). p53+ in non-tumoral Barrett mucosa (focal i.e. one or more foci of positive glands vs. diffuse) and its localization (surface epithelium vs. basis of crypts) was analyzed in function of architectural and cytological features of IEN (nuclear enlargement, pseudostratification, maturation). Results: p53+ was detected in 90% of cases (focal: 45%; diffuse: 45%). Diffuse p53+ correlates with carcinoma. Five cases did contain 1 or 2 p53+ foci, 4 cases 4 up to 22 foci. No association was found with architectural abnormalities. A significant difference (p<0.0001)was observed in nuclear enlargement (18% vs. 53%), pseudostratification (11% vs. 79%) and absence of maturation of the epithelium (8% vs. 59%). Focal p53+ was associated with clear-cut morphological IEN in 17% of foci, with a significant lower sensitivity (20% vs. 80%), specificity (27% vs. 73%) and diagnostic accuracy (24% vs 76%) than diffuse p53+ (p<0.0001). Ki-67+ did not improve the diagnostic accuracy. p53+ surface epithelium equals IEN. Conclusion: p53+ was found in two patterns (focal vs. diffuse), whereby the latter correlates to morphological IEN and the former may be indicative of early changes which are not yet detectable by routine morphology. No significant financial relationships to disclose.
Epidemiology of meningococcal meningitis and changes in the surveillance system in Poland, 1970-2006
Authors: O Gryniewicz, J Kolbusz, M Rosinska, A Zielinski, P Stefanoff
Journal: Eurosurveillance (2007)

The objective of this study was to describe the general features of meningococcal meningitis epidemiology in 1970-2006 in Poland, in the context of changes made in surveillance system methods. Because of limited availability of case-based data, a more detailed analysis was performed only for the period 1994-2006 with special focus on case-fatality and diagnostic certainty. The reported annual number of meningococcal meningitis cases reached its peak of 416 (incidence 1.2 per 100,000) in 1981, after which it decreased to 76 cases in 2003 (incidence 0.2), and then increased to 151 cases in 2006 (incidence 0.4 per 100,000). The observed decrease was consistent with the decline in the number of live births and the drop in mortality from meningococcal disease observed using an independent reporting of death certificates. In 1994-2006, 1,677 cases of meningococcal meningitis were registered, with annual incidence varying between 0.2 and 0.5 per 100,000 inhabitants. Median age of patients was 4 years and 73% of cases were under 18 years of age. The majority of cases were caused by group B meningococci, but a trend towards increasing proportion of serogroup C has been identified. Meningococcal meningitis only was reported in 79% of cases, and meningitis with concomitant septicaemia in 21%. The overall case fatality was 3.7% - 4.5% in cases of meningitis only, and 7.1% in cases of meningitis with septicaemia. Based on the case definition introduced in 2005, 88.1% of the cases would be classified as confirmed and 4.8% as probable, whereas 7.1% would not fulfil the criteria of the case definition. Although diagnostic certainty of reported cases has improved in recent years, it is still problematic. Further efforts are needed to increase the proportion of serogrouped cases and assess the burden of meningococcal disease in Poland.
Comparison of surgical and endovascular approaches in the management of multiple intracranial aneurysms
Authors: Qing-Lin Dong, Bu-Lang Gao, Zhong-Rong Cheng, Yan-Yan He, Xue-Jing Zhang, Qiong-Ying Fan, Cong-Hui Li, Song-Tao Yang, Cheng Xiang
Journal: International Journal of Surgery (2016)
Abstract 61: miR-28 Induces Oxidative Stress via Nrf2 in Right Ventricular Failure but not in Left Ventricular Failure
Authors: Sushma Reddy, Dong-Qing Hu, Mingming Zhao, Eddie Blay, Giovanni Fajardo, Daniel Bernstein
Journal: Circulation Research (2014)

MicroRNAs (miRs) are crucial regulators of cardiac remodeling in left ventricular hypertrophy and failure (LVH/LVF). However, there is minimal data on their role in right ventricular hypertrophy and failure (RVH/RVF), a risk for patients with congenital heart disease or pulmonary hypertension. Utilizing a murine model of RVH/RVF, we have described RV-specific overexpression of miR-28, not found in LVH/LVF. We used this model to evaluate miR-28 regulation of its downstream target Nrf2, a master regulator of antioxidant defenses, and a potential mechanism of the enhanced susceptibility of the RV to fail under pressure overload. Methods: miR-28 and Nrf2 gene and protein expression and ROS production and antioxidant defenses were assessed at 10d in RVH/RVF (pulmonary artery banding) and LVH/LVF (aortic banding). miR-28 was overexpressed in HEK293 cells and Nrf2 and ROS production assessed. Plasma miRs were also profiled. Results: Mice developed RVH by d4, at which time miR-28 was not increased vs. sham, and RVF by d10, when miR-28 was increased 2-fold. This was accompanied by decreases in Nrf2 gene (2-fold) and protein (0.4±0.2 vs. 0.8±0.1, p&lt;0.05) expression, Nrf2-regulated SOD expression (2-fold), and SOD activity (80±15% vs. 90±18%, p&lt;0.05). ROS production (4HNE) was increased (1.5±0.1 vs. 1.0±0.1, p&lt;0.05). In contrast, at the same stage of LVH/LVF, miR-28 is not increased, Nrf2 expression is increased (0.45±0.2 vs. 0.1±0.02, p&lt;0.05) and SOD is unchanged. Lentiviral miR-28 overexpression in HEK293 cells showed downregulation of Nrf2, SOD and heme oxygenase expression (1.6-2.1 fold) with a 35% increase in ROS production (p&lt;0.05). Finally, plasma miR-28 decreased with the progression from RVH to RVF in mice, and this was confirmed in children undergoing pulmonary valve replacement for RV failure (patients vs controls, n=4/group). Conclusions: Our data show that RV-specific miR-28 enhances RVH/RVF through suppression of Nrf2 signaling and increased oxidative stress. Although we did not find Nrf2 downregulation at the same stage of LVH/LVF, others have shown this at 4-6 wks, suggesting this process may occur earlier in RVF vs. LVF. Finally, miR-28 plasma expression may be a biomarker for early RVF in patients.
Validation of the Baveno VI criteria to identify low risk cirrhotic patients not requiring endoscopic surveillance for varices
Authors: James B Maurice, Edgar Brodkin, Frances Arnold, Annalan Navaratnam, Heidi Paine, Sabrina Khawar, Ameet Dhar, David Patch, James O’Beirne, Raj Mookerjee, Massimo Pinzani, Emmanouil Tsochatzis, Rachel H. Westbrook
Journal: Journal of Hepatology (2016)
P0290 : Placental growth factor inhibition modulates the interplay between hypoxia and the unfolded protein response in hepatocellular carcinoma
Authors: Y.-P. Vandewynckel, D. Laukens, L. Devisscher, A. Paridaens, E. Bogaerts, X. Verhelst, A. Van den Bussche, S. Raevens, C. Van Steenkiste, B. Jonckx, L. Libbrecht, A. Geerts, P. Carmeliet, H. Van Vlierberghe
Journal: Journal of Hepatology (2015)
Uncoupling in the expression of platelet GP IIb/IIIa in human endothelial cells and K562 cells: absence of immunologic crossreactivity between platelet GP IIb and the vitronectin receptor alpha chain [see comments]
Authors: N Kieffer, JL Wautier, L Coulombel, M Titeux, MP Wautier, W Vainchenker, C Ruan, J Breton-Gorius
Journal: Blood (1988)